S-1/A: VivoSim Labs Seeks $4M Amidst Going Concern Doubts

Sentiment:

Registration Statement Amendment 31 March 2026 10:17 AM

VivoSim Labs, Inc. files an S-1/A for a best efforts public offering of up to $4 million in common stock and warrants, aiming to fund operations through 2027 despite significant accumulated losses and auditor's going concern warning.

Capital raiseA best efforts public offering of up to $4,000,000 in common stock, pre-funded warrants, and common warrants.The offering is split into an Initial Tranche (up to $3,000,000) and a conditional Second Tranche (up to $1,000,000).The company believes that the net proceeds of $3.4 million from this offering, combined with an additional $5.0 million in net proceeds from future sales of securities or otherwise throughout 2026, will meet its capital needs through the end of 2027.The company has an existing Sales Agreement with JonesTrading Institutional Services LLC, under which it may sell up to $3.1 million of common stock.

Worse than expectedThe company explicitly states that current cash on hand is not sufficient to fund operations beyond July 2026, indicating a critical liquidity shortfall.The independent auditor's report for the fiscal year ended March 31, 2025, includes explanatory language about substantial doubt regarding the company's ability to continue as a going concern.The offering is a 'best efforts' basis with no minimum, meaning the company may not raise the necessary capital to address its financial needs, and investors will not receive a refund if the offering is insufficient.The significant accumulated deficit of $350.2 million highlights a history of substantial losses.

Summary

VivoSim Labs, Inc. (VIVS) is conducting a best efforts public offering to raise up to $4,000,000 through the sale of common stock, pre-funded warrants, and common warrants.
The offering is structured in two tranches: an Initial Tranche for up to $3,000,000 and a conditional Second Tranche for up to $1,000,000, dependent on stock price and trading volume conditions.
The company's business model has shifted to providing pharmaceutical and biotechnology services, focusing on 3D human tissue models for liver and intestinal toxicology, following the sale of its FXR program for $10.0 million in March 2025.
VivoSim Labs reported a net loss of $2.7 million for the three months ended December 31, 2025, and an accumulated deficit of $350.2 million since inception.
Current cash on hand is insufficient to fund operations beyond July 2026; the company believes the offering's net proceeds of $3.4 million, combined with an additional $5.0 million raise in 2026, would fund operations through the end of 2027.
The offering includes common warrants with a cashless exercise provision that could lead to substantial dilution for existing stockholders, potentially requiring the issuance of shares far exceeding currently authorized amounts.
The company's independent registered public accounting firm included explanatory language in its report for the fiscal year ended March 31, 2025, indicating substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to the severe financial distress indicated by the going concern warning and insufficient cash runway, coupled with the high dilution risk of the offering, despite a promising business model pivot.

Positives

The company has successfully pivoted its business model to focus on 3D human tissue models for drug testing, a field with anticipated accelerated adoption following FDA announcements.
VivoSim's liver toxicology platform demonstrated a best-in-class predictive power of 87.5% sensitivity for challenging liver toxicity cases and 100% specificity (no false positives).
The sale of the FXR program in March 2025 for $10.0 million (with $9.0 million upfront and $1.0 million in escrow) provides immediate capital and potential future milestones of up to $50.0 million.
The Preclinical IBD Program, a novel drug candidate, has advanced to the medicinal chemistry stage, with a goal for an Investigational New Drug (IND) filing with the FDA by December 2026.

Negatives

The company incurred substantial net losses of $2.7 million for the three months ended December 31, 2025, and has an accumulated deficit of $350.2 million since inception.
Current cash on hand is not sufficient to fund operations beyond July 2026, indicating an urgent need for capital.
The independent auditor's report for the fiscal year ended March 31, 2025, contains explanatory language regarding substantial doubt about the company's ability to continue as a going concern.
The offering is a 'best efforts' offering with no minimum amount of securities required to be sold, meaning the company may not raise the full $4.0 million or sufficient capital for its business plans.
New investors will experience immediate and substantial dilution of $0.36 per share based on the assumed offering price.
The cashless exercise provision of the common warrants is highly likely to result in no additional cash proceeds for the company and could lead to substantial dilution for stockholders, potentially requiring the issuance of shares far exceeding the number registered or even authorized.

Risks

The company needs to raise capital in this offering to support operations, and failure to do so will materially adversely impact its financial position.
Substantial doubt exists about the company's ability to continue as a going concern, as noted by its independent registered public accounting firm.
There is no assurance that the conditions for closing the Second Tranche of the offering (stock price and trading volume thresholds) will be satisfied, potentially limiting the total capital raised.
Management has broad discretion over the use of net proceeds from the offering, which may not align with stockholder value creation.
Investors purchasing securities will experience immediate and substantial dilution, and further dilution is likely upon the cashless exercise of common warrants.
The company may not have registered sufficient shares of common stock (250% of initially issuable shares) or sufficient authorized shares (196.5 million available vs. potential 720 million+ needed) to cover all shares that might be issued upon a cashless exercise of common warrants.
Because there is no minimum offering amount, investors will not receive a refund if insufficient capital is raised to pursue business goals.
Future sales of additional equity or convertible debt securities could result in further dilution to stockholders and cause the stock price to fall.
There is no established public trading market for the common warrants or pre-funded warrants, limiting their liquidity.
The company could fail to maintain its listing on the Nasdaq Capital Market due to minimum bid price or stockholders' equity requirements, which could harm liquidity and ability to raise capital.
Strategic transactions, including acquisitions or divestitures, carry numerous risks such as integration difficulties, financing challenges, and potential negative impacts on financial results.
Changes to tax laws, such as the One Big Beautiful Bill Act (OBBA) signed on July 4, 2025, could adversely affect the company or holders of its common stock.
Ongoing litigation, specifically the H.C. Wainwright & Co., LLC lawsuit, could be time-consuming, expensive, and divert management resources, potentially leading to substantial payments or changes in business practices.

Future Outlook

VivoSim Labs anticipates accelerated adoption of human tissue models following the FDA's April 2025 announcement favoring non-animal testing methods. The company expects to expand its offerings to include bespoke services in investigational toxicology and drug mechanism elucidation. A key strategic goal is to have a product candidate from its Preclinical IBD Program ready for an Investigational New Drug (IND) filing with the FDA by December 2026. VivoSim plans to market its services directly to pharmaceutical and biotech companies and partner with contract research organizations to grow its client portfolio.

Management Comments

We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration (FDA) announcement on April 10, 2025, to refine animal testing requirements in favor of these non-animal NAM methods.
We expect to offer bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of these complex human tissue models.
We continue to advance our Preclinical IBD Program, with the goal of having a product candidate ready for an Investigational New Drug with the FDA by December 2026.
Our services offer the potential benefit of reducing the significant risk and cost of bringing therapeutics to market through the regulatory process.
Our liver toxicology platform had a best-in-class predictive power, with 87.5% sensitivity for challenging liver toxicity cases and 100% specificity, which we believe at 87.5% is a world's best.

Industry Context

StockSavvy.ai notes that VivoSim Labs' strategic pivot towards 3D human tissue models for drug testing aligns well with the U.S. Food and Drug Administration's (FDA) April 2025 announcement, which signals a shift towards non-animal New Approach Methodologies (NAMs). This regulatory tailwind could significantly boost demand for VivoSim's services, positioning the company favorably within the pharmaceutical and biotechnology services sector. The industry faces high drug development costs and failure rates, particularly due to unexpected toxicity, making VivoSim's predictive toxicology platforms a potentially valuable tool for reducing risk and accelerating drug candidates to market.

Comparison to Industry Standards

VivoSim's liver toxicology platform demonstrated 87.5% sensitivity for challenging liver toxicity cases, which the company claims is a 'world's best' for identifying known liver-toxic drugs using NAMkind liver models.
The platform achieved 100% specificity, meaning no non-liver toxic compounds were incorrectly identified as toxic, a critical metric for reliability in drug screening.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	The Certificate of Incorporation establishes a classified board of directors divided into three classes with staggered three-year terms, with only one class subject to election each year.	NA	This structure makes it more difficult for stockholders to replace a majority of directors, potentially discouraging hostile takeovers and promoting management continuity.
Director Removal	Directors may be removed only for cause.	NA	Limits stockholders' ability to remove directors without specific justification, further entrenching the current board.
Special Stockholder Meetings	A special meeting of stockholders may be called only by the chairperson of the Board, chief executive officer, president (in absence of CEO), or a majority of authorized directors.	NA	Prohibits individual stockholders from calling special meetings, potentially delaying consideration of stockholder proposals or actions.
Stockholder Action by Written Consent	Eliminates the right of stockholders to act by written consent without a meeting unless approved in advance by a Board resolution.	NA	Requires formal meetings for stockholder actions, making it harder for a majority holder to act quickly without Board approval.
Advance Notice Requirements	Establishes advance notice procedures for stockholder proposals and director nominations at meetings.	NA	May preclude stockholders from bringing matters or nominations if proper procedures are not followed, potentially deterring proxy solicitations.
Cumulative Voting	The Certificate of Incorporation does not permit stockholders to cumulate their votes in the election of directors.	NA	Allows holders of a majority of common stock to elect all directors, potentially limiting minority stockholder representation.
Preferred Stock Issuance	The Board is authorized to issue up to 25,000,000 shares of undesignated preferred stock with voting or other rights/preferences as designated by the Board, without further stockholder action.	NA	Provides flexibility for acquisitions but could be used to impede a change in control or adversely affect common stock voting power and market price.
Delaware Law Applicability	The company is subject to Section 203 of the DGCL, which prohibits interested stockholders from engaging in business combinations for three years unless approved.	NA	May have an anti-takeover effect for transactions not approved by the Board.
Choice of Forum	Bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain corporate actions.	NA	May limit stockholders' ability to bring claims in other judicial forums, potentially increasing litigation costs for non-Delaware residents.

Legal Proceedings

H.C. Wainwright & Co., LLC filed a complaint on August 27, 2024, alleging breach of a tail financing provision from a May 2023 engagement agreement, seeking compensatory and consequential damages and attorneys' fees.
VivoSim Labs filed an amended answer and counterclaimed on September 2, 2025, seeking rescission, fraudulent inducement, and breach of contract, alleging H.C. Wainwright misrepresented services and breached duties.

Stakeholder Impact

Shareholders: Face significant dilution from the offering and potential future cashless exercises of warrants. Risk of substantial loss of investment due to the company's going concern issues and the 'best efforts' nature of the offering. Potential for delisting from Nasdaq could severely impact liquidity and market price.
New Investors: Will experience immediate and substantial dilution upon purchasing shares in this offering.
Placement Agent (Joseph Gunnar & Co., LLC): Will receive a 7.5% cash fee on gross proceeds and Placement Agent Warrants, benefiting from the capital raise regardless of the company's long-term success.
Customers (Pharmaceutical and Biotech Companies): Stand to benefit from VivoSim's advanced 3D human tissue models for drug testing, potentially reducing drug development risks and costs.

Next Steps

Complete the Initial Tranche of the public offering, expected not later than one business day following commencement.
Potentially complete the Second Tranche of the offering 30 days after the Initial Tranche closing, subject to specific stock price and trading volume conditions.
Continue advancing the Preclinical IBD Program with the goal of filing an Investigational New Drug (IND) application with the FDA by December 2026.
Market liver toxicology predictive screening and research services directly to pharmaceutical and biotech companies.
Partner with contract research organizations to expand client portfolio for toxicology services.
Potentially raise an additional $5.0 million in net proceeds through the sale of securities or otherwise throughout 2026 to extend capital needs through the end of 2027.
Defend against H.C. Wainwright & Co., LLC's claims and pursue counterclaims vigorously in ongoing litigation.

Key Dates

Date	Description
2007-04-01	Organovo, Inc. incorporated in Delaware.
2009-03-24	License Agreement between Organovo, Inc. and the Curators of the University of Missouri.
2010-03-12	License Agreement between the Company and the Curators of the University of Missouri.
2012-01-01	Organovo Holdings, Inc. incorporated in Delaware.
2012-02-01	Acquisition of Organovo, Inc. by Organovo Holdings, Inc.
2016-07-26	Registration Statement on Form 8-A (File No. 001-35996) filed with the SEC.
2016-08-08	Common stock traded on Nasdaq Global Market under symbol ONVO.
2018-03-16	Sales Agreement entered into with JonesTrading Institutional Services LLC.
2019-12-27	Common stock traded on Nasdaq Capital Market under symbol ONVO.
2023-03-01	Beginning of period for recent sales of unregistered securities.
2023-05-01	Engagement agreement entered into with H.C. Wainwright & Co., LLC.
2023-12-06	Issued 5,482 unregistered shares of common stock to a marketing firm.
2024-08-27	H.C. Wainwright & Co., LLC filed a complaint against the company.
2024-10-18	Company filed an answer to H.C. Wainwright's complaint.
2025-03-01	Sale of FXR program completed.
2025-04-10	U.S. Food and Drug Administration (FDA) announcement to refine animal testing requirements in favor of non-animal NAM methods.
2025-04-24	Corporate name changed to VivoSim Labs, Inc. and common stock began trading on Nasdaq Capital Market under VIVS.
2025-05-01	Findings presented at the Digestive Disease Week scientific conference regarding liver toxicology platform.
2025-09-02	Company filed an amended answer and counterclaimed against H.C. Wainwright.
2025-12-31	Common stock outstanding: 2,607,962 shares; Net tangible book value: $3.2 million, or $1.23 per share; Net losses for the three months ended: $2.7 million; Accumulated deficit through: $350.2 million.
2026-03-26	Last reported sale price of common stock on Nasdaq Capital Market was $1.69.
2026-03-31	Filing date of Amendment No. 1 to Form S-1 Registration Statement.
2026-04-30	Offering termination date, unless Initial Tranche closes earlier or company terminates.
2026-07-01	Estimated date when current cash on hand will be insufficient to fund operations.
2026-08-17	Placement Agent's Participation Right expires.
2026-12-01	Goal to have Preclinical IBD Program product candidate ready for IND with FDA.
2027-01-01	Estimated period through which net proceeds from offering plus additional $5M would fund operations.
2029-05-13	Expiration date for outstanding warrants to purchase 539,060 shares of common stock.

Recommendation

strong sell

The filing reveals severe financial distress, including an explicit 'going concern' warning from auditors and a very short cash runway (until July 2026). The 'best efforts' offering with no minimum amount provides no assurance of sufficient capital, and the highly dilutive nature of the warrants, particularly the cashless exercise provision, poses an existential threat to existing shareholder value. While the business model pivot and technology show promise, the immediate and substantial financial risks, coupled with ongoing litigation and Nasdaq listing concerns, make this a high-risk investment with a strong likelihood of further capital erosion. A seasoned investor would prioritize capital preservation given these red flags.

Keywords

VivoSim Labs, VIVS, SEC filing, S-1/A, public offering, common stock, warrants, pre-funded warrants, biotechnology, pharmaceutical services, 3D human tissue models, liver toxicology, intestinal toxicology, drug development, NAM models, IBD program, capital raise, dilution, going concern, Nasdaq listing, risk factors

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.